Two years after Alex Denner activist attack, Ironwood plots mass layoffs as last clinical program goes up in smoke
A year and a half ago, when Ironwood finished splitting itself in two, they were left with just a pair of experimental medicines in the clinic: a reformulation of Linzess, their approved drug for irritable bowel syndrome, and a new drug for persistent acid reflux called IW-3718.
In May, the Linzess formulation failed a Phase II study. And now, in part two of a year-long double-whammy for the Boston pharma, IW-3718 proved ineffective in its own large study. Both programs will be discontinued, marking a major setback for Ironwood and leaving the company facing an empty pipeline, huge layoffs and, two years splitting amid pressure from Alex Denner, another restructuring.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.